Gilteritinib results in higher remission and transplant rates than midostaurin but does not increase the post-induction mutational MRD negative rate: Results of the phase 2 randomized PrECOG 0905 study in newly diagnosed FLT3 mutated AML Meeting Abstract
| Authors: | Luger, S.; Chen, L.; Pratz, K. W.; Loghavi, S.; Perl, A. E.; Altman, J. K.; Redner, R. L.; Fathi, A. T.; Qasrawi, A.; Asch, A. S.; Jeyakumar, D.; Foran, J. M.; Shah, M.; Kolitz, J. E.; Berman, E.; Wilde, L.; Abedin, S.; Kota, V. K.; Gundabolu, K.; O'Dwyer, K. M.; Curran, E. K.; Kishtagari, A.; Ross, K.; Sun, Z.; Litzow, M. R. |
| Abstract Title: | Gilteritinib results in higher remission and transplant rates than midostaurin but does not increase the post-induction mutational MRD negative rate: Results of the phase 2 randomized PrECOG 0905 study in newly diagnosed FLT3 mutated AML |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 222 |
| End Page: | 223 |
| Language: | English |
| ACCESSION: | WOS:001414317000021 |
| DOI: | 10.1182/blood-2024-201595 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
